Page last updated: 2024-12-07
n-nitrosopropranolol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
N-nitrosopropranolol: structure for (E)-isomer & RN given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 128614 |
| CHEMBL ID | 143513 |
| MeSH ID | M0113649 |
Synonyms (12)
| Synonym |
|---|
| brn 4875981 |
| ccris 4203 |
| n-nitrosopropanolol |
| n-nitrosopropranolol |
| 2-propanol, 1-((1-methylethyl)nitrosoamino)-3-(1-naphthalenyloxy)- |
| CHEMBL143513 |
| 84418-35-9 |
| n-(2-hydroxy-3-naphthalen-1-yloxypropyl)-n-propan-2-ylnitrous amide |
| DTXSID301004684 |
| n-{2-hydroxy-3-[(naphthalen-1-yl)oxy]propyl}-n-propan-2-ylnitrous amide |
| EN300-18585762 |
| 1-(naphthalen-1-yloxy)-3-[nitroso(propan-2-yl)amino]propan-2-ol |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (6)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID191494 | Toxicity (Ames Salmonella Test) in the presence of rat liver S-9 fraction in TA-100 strain (4*10e6 dilution) | 1983 | Journal of medicinal chemistry, Mar, Volume: 26, Issue:3 | Derivatives of beta-adrenergic antagonists. N-Nitrosopropranolol and N-hydroxypropranolol and its aldonitrone. |
| AID184702 | Mutagenic activity (Ames Salmonella Test) in the presence of rat liver S-9 fraction in TA-100 strain | 1983 | Journal of medicinal chemistry, Mar, Volume: 26, Issue:3 | Derivatives of beta-adrenergic antagonists. N-Nitrosopropranolol and N-hydroxypropranolol and its aldonitrone. |
| AID184703 | Mutagenic activity (Ames Salmonella Test) in the presence of rat liver S-9 fraction in TA-100 strain at a conc. of 1000 ug | 1983 | Journal of medicinal chemistry, Mar, Volume: 26, Issue:3 | Derivatives of beta-adrenergic antagonists. N-Nitrosopropranolol and N-hydroxypropranolol and its aldonitrone. |
| AID191495 | Toxicity (Ames Salmonella Test) in the presence of rat liver S-9 fraction in TA-100 strain (4*10e7 dilution) | 1983 | Journal of medicinal chemistry, Mar, Volume: 26, Issue:3 | Derivatives of beta-adrenergic antagonists. N-Nitrosopropranolol and N-hydroxypropranolol and its aldonitrone. |
| AID184705 | Mutagenic activity (Ames Salmonella Test) in the presence of rat liver S-9 fraction in TA-98 strain | 1983 | Journal of medicinal chemistry, Mar, Volume: 26, Issue:3 | Derivatives of beta-adrenergic antagonists. N-Nitrosopropranolol and N-hydroxypropranolol and its aldonitrone. |
| AID184706 | Mutagenic activity (Ames Salmonella Test) in the presence of rat liver S-9 fraction in TA-98 strain at a conc. of 1000 ug | 1983 | Journal of medicinal chemistry, Mar, Volume: 26, Issue:3 | Derivatives of beta-adrenergic antagonists. N-Nitrosopropranolol and N-hydroxypropranolol and its aldonitrone. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 27.27
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.27) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||